Dynavax Technologies traded at $15.50 this Friday February 6th, increasing $0.01 or 0.06 percent since the previous trading session. Looking back, over the last four weeks, Dynavax Technologies gained 0.58 percent. Over the last 12 months, its price rose by 17.87 percent. Looking ahead, we forecast Dynavax Technologies to be priced at 15.01 by the end of this quarter and at 13.66 in one year, according to Trading Economics global macro models projections and analysts expectations.
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing novel vaccines. The Company's products include HEPLISAV-B and CpG 1018TM. The HEPLISAV-B is for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The Company also manufactures and sells CpG 1018TM, the adjuvant used in HEPLISAV-B. The Company also engaged in developing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.